Abstract library

17 results for "cyclin D1".
#409 Activation of cdk4/Cyclind D1 and the Associated Attenuation of Rb Function in Pancreatic Neuroendocrine Tumors (Pan-NETs)
Introduction: Pan-NET poses challenges in clinical management due to the lack of identifications of key oncogenic pathways in this neoplasm. There are no reliable biomarkers to predict the recurrence and progression and treatment option is limited. Genetic changes in Rb pathway can lead to Pan-NET formation in mice. Genomic investigations in humans have not revealed Rb pathway mutation.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Laura Tang
Authors: Tang L
#87 Alterations of E-cadherin, beta-catenin and caveolin-1 expression in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) comprise a heterogeneous group of neoplasm with different histological patterns and biological behavior. Only limited information is available on immunohistochemical prognostic factors of disease. Alterations in the cell-cell adhesion system are closely associated with cell invasion and metastasis in many malignancies, including those of endocrine origin. Abnormal expression of E-cadherin and beta-catenin has been reported to play an important role in these processes. Caveolin-1 has recently been identified as a tumor metastasis modifier factor, which might increase the cell metastasis potential through the interaction with E-cadherin. However, the role of caveolin-1 in GEP NETs cell invasion remains unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Vera V Delektorskaya
#962 Cyclin D1 Levels are Involved in the Resistance to m-TOR Inhibitors in Human Bronchial Carcinoids
Introduction: Bronchial carcinoids (BC) are still orphans of medical therapy. We previously demonstrated that the typical BC human cell line NCI-H727 is sensitive to Everolimus, in terms of cell viability reduction, while the atypical human BC cell line NCI-H720 is not. However, the mechanisms underlying this phenomenon have not been fully clarified.
Conference: 11th Annual ENETS Conference (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Master degree Katiuscia Benfini
Keywords: BC, mTOR
#1999 Study of Cell Cycle Protein Expression Pattern in Bronchial Carcinoids: A New Potential Target for Medical Therapy?
Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Giulia Bresciani
#1507 The CDK4/6 Inhibitor Palbociclib Induces Anti-proliferative Mechanisms in Gastroenteropancreatic Neuroendocrine Neoplasms In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with heterogeneous molecular backgrounds and mostly unknown druggable driver mutations. Especially for the midgut NENs effective treatment options are limited. The retinoblastoma pathway is often inactive due to CDK4/6 overexpression in pancreatic NENs. Palbociclib is a FDA approved (ER-positive and HER2-negative breast cancer) cyclin-dependent kinases 4 and 6 inhibitor and might impair cell cycle progression and proliferation.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#1100 Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - Genetics, epigenetics, miRNAs
Presenting Author: Federico Canzian
#2165 A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors
Introduction: Increased cyclin dependent kinases 4, 6 (cdk 4/6) activity is noted in the majority of well differentiated foregut neuroendocrine tumors (fNETs) due to mutations in MENIN and other aberrations. These tumors also have preserved Rb function making cdk 4/6 inhibitors attractive agents for therapy.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Assistant Profes Arvind Dasari
#1090 p27kip1 Is Involved in the Resistance of Human Bronchial Carcinoids to m-TOR Inhibitors
Introduction: Bronchial carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that the typical BC human cell line NCI-H727 is sensitive to Everolimus (E), in terms of cell viability reduction, with a G0 cell-cycle arrest, while the atypical human BC cell line NCI-H720 is not. The mechanisms underlying this phenomenon have not been clarified
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Master Degree Katiuscia Benfini
Keywords: RAD001, BC, p27kip1, Cell cycle
#788 A Novel Animal Model for Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer originating from calcitonin-producing C-cells. Surgical resection is the most effective treatment currently available. Understanding the molecular pathways mediating MTC is crucial for the development of novel therapies. Cyclin-dependent kinase 5 (Cdk5) and its activators, p35 and p25, have recently been implicated in MTC etiology. P25 is a cleavage product of p35 and the binding of p25 to Cdk5 leads to aberrant Cdk5 activity.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Karine Pozo
Authors: Pozo K, Castro-Rivera E, Tan C, Siegl V, ...
Keywords: thyroid, Cdk5
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MASTER DEGREE Katiuscia Benfini